Alluvi, formerly BI 4744, presents a notable breakthrough in weight management treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/